fbpx
Today
16:01 07 Dec 2021

An innovative drug to treat tuberculosis registered in Ukraine

The innovative drug Pretomanid to treat tuberculosis, which has a wide medical resistance, has been registered in Ukraine.

The Ministry of Health announced this, Rubryka reports.

"Introducing the new TB drug Pretomanid in Ukraine is one step closer to the most valuable thing: saving the lives of about 1,300 people with resistant tuberculosis, as well as the ability to effectively treat at least 90% of people with TB according to the WHO recommended target. It will greatly contribute to decreasing prevalence and mortality from drug-resistant tuberculosis," said Yana Terleieva, head of the TB's Public Health Control and Counteraction Department.

It is noted that Ukraine became the 5th country in the world to grant the use of Pretomanid by regulatory authorities, which once again confirms the country's global commitment to implementing modern approaches to the treatment of drug-resistant tuberculosis.

The use of a new drug is shown in the innovative mode BPal in terms of surgical studies when instead of 4-5 potent drugs they used three drugs with a shorter duration of administration.

The registration of Pretomanid was the result of long-term coordinated work of the Ministry of Health, the Center for Public Health, the WHO, the Green Light Committee, the Global Fund to Fight AIDS, TB and Malaria, the Global Medical Fund, 100% LIFE, and Doctors Without Borders.

The Ministry of Health also reported that Pretomanid was included in the nomenclature list of drugs to be purchased in early 2021. The Ministry of Health has also allocated the necessary resources for the purchase of the drug through the State Enterprise "Medical Procurement of Ukraine."

Category:
Health

If you have found a spelling error, please, notify us by selecting that text and pressing Ctrl+Enter.

Add comment

E-mail is already registered on the site. Please use the Login form or enter another.

You entered an incorrect username or password

Sorry, you must be logged in to post a comment.

Spelling error report

The following text will be sent to our editors: